ARWR · Arrowhead Pharmaceuticals, Inc. · Webcasts, Transcripts & Audio
$47.78
+0.63 (+1.34%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q4 2026 earnings call transcript
Market Cap
$6.75B
Shares
141.37M
Volume · Nov 13
3.11M
Avg daily vol (3M)
1.92M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Arrowhead Pharmaceuticals, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Arrowhead Pharmaceuticals, Inc. (ARWR), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-12-02
Arrowhead Pharmaceuticals, Inc. (ARWR) December 2, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-12-02
Arrowhead Pharmaceuticals, Inc. (ARWR) December 2, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-18
Arrowhead Pharmaceuticals, Inc. (ARWR) November 18, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q4
2026-11-12
Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2026 Earnings Call Transcript
Confident tone
SHTG launch opportunity
Redempla FCS commercialization
Pipeline development
Revenue
$37.79M*
▼ 85.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Conference
Investor event
2026-09-15
Arrowhead Pharmaceuticals, Inc. (ARWR) September 15, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-08-04
Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2026 Earnings Call Transcript
Confident tone
SHASTA Phase 3 results in SHTG
FCS launch / commercial momentum
Priority Review Voucher / regulatory acceleration
Revenue
$75.25M
▲ 171% YoY Diluted EPS
$-1.36
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-10
Arrowhead Pharmaceuticals, Inc. (ARWR) June 10, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-03
Arrowhead Pharmaceuticals, Inc. (ARWR) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-20
Arrowhead Pharmaceuticals, Inc. (ARWR) May 20, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-13
Arrowhead Pharmaceuticals, Inc. (ARWR) May 13, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-05-07
Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2026 Earnings Call Transcript
Confident tone
Commercial launch of Redemplo (FCS)
Pipeline breadth and innovation
Shasta-3/4 Phase 3 readout in SHTG
Revenue
$73.74M
▼ 86.4% YoY Diluted EPS
$-0.93
▼ 133.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-02-05
Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2026 Earnings Call Transcript
Confident tone
Redempla launch and commercialization
Mixed hyperlipidemia / Aero-RPA
Caution on early launch and data interpretation
Revenue
$264.03M
▲ 10461.3% YoY Diluted EPS
$0.22
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Investor Update
Investor event
2026-01-06
Arrowhead Pharmaceuticals, Inc. (ARWR) January 6, 2026 Investor Update
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2025-11-25
Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2025 Earnings Call Transcript
Confident tone
Rodemplo FDA approval and launch
Leadership transition
Shasta Phase III studies
Revenue
$256.47M*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-08-07
Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2025 Earnings Call Transcript
Confident tone
Plozasiran FCS approval and SHTG program
Zodasiran HoFH Phase III
Sarepta partnership
Revenue
$27.77M
Diluted EPS
$-1.26
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-05-12
Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2025 Earnings Call Transcript
Confident tone
Plozasiran (FCS) launch and regulatory
Obesity programs (INHBE / ALK7)
CNS and BBB platform
Revenue
$542.71M
Diluted EPS
$2.75
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-02-10
Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2025 Earnings Call Transcript
Confident tone
Plozasiran commercial launch and value proposition
Zodasiran HoFH Phase III
Obesity pipeline (ARO-IoN-HPE, ARO-ALK7)
Revenue
$2.50M
▼ 29.6% YoY Diluted EPS
$-1.39
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2024-11-26
Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2024 Earnings Call Transcript
Confident tone
Sarepta licensing and collaboration deal
Wholly-owned cardiometabolic pipeline focus
Pulmonary platform partnering
Revenue
$0*
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-08-08
Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2024 Earnings Call Transcript
Confident tone
Plozasiran Commercial Opportunity
Phase 3 PALISADE Study
Earlier-Stage Pipeline (Obesity, Lung, Kidney)
Revenue
$0
▼ 100% YoY Diluted EPS
$-1.38
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-05-09
Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2024 Earnings Call Transcript
Confident tone
Cardiometabolic focus and pipeline value
Obesity and metabolic disease expansion
Plozasiran FCS approval and commercial launch
Revenue
$0
▼ 100% YoY Diluted EPS
$-1.02
▼ 326.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-02-06
Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2024 Earnings Call Transcript
Confident tone
Plozasiran / FCS Phase 3
Zodasiran / ANGPTL3
Pipeline breadth and partnerships
Revenue
$3.55M
▼ 94.3% YoY Diluted EPS
$-1.24
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2023-11-29
Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2023 Earnings Call Transcript
Revenue
$16.10M*
▼ 49% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-08-07
Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2023 Earnings Call Transcript
Revenue
$15.82M
▼ 51.2% YoY Diluted EPS
$-0.96
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-05-02
Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2023 Earnings Call Transcript
Revenue
$146.27M
▼ 3.6% YoY Diluted EPS
$0.45
▲ 9.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2022-12-31
Date not confirmed
Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2023 Earnings Call Transcript
Revenue
$62.55M
▲ 127.9% YoY Diluted EPS
$-0.39
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2022-11-28
Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2022 Earnings Call Transcript
Revenue
$31.57M*
▼ 17.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-08-04
Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2022 Earnings Call Transcript
Revenue
$32.41M
▼ 29.4% YoY Diluted EPS
$-0.68
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-05-10
Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2022 Earnings Call Transcript
Revenue
$151.81M
▲ 362.7% YoY Diluted EPS
$0.41
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-02-02
Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2022 Earnings Call Transcript
Revenue
$27.44M
▲ 28.8% YoY Diluted EPS
$-0.60
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2021-11-22
Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2021 Earnings Call Transcript
Revenue
$38.28M*
▲ 401.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-08-05
Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2021 Earnings Call Transcript
Revenue
$45.89M
▲ 67.6% YoY Diluted EPS
$-0.29
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-05-04
Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2021 Earnings Call Transcript
Revenue
$32.81M
▲ 39.4% YoY Diluted EPS
$-0.26
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-02-04
Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2021 Earnings Call Transcript
Revenue
$21.30M
▼ 27.7% YoY Diluted EPS
$-0.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2020-11-23
Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2020 Earnings Call Transcript
Revenue
$7.63M
▼ 82.4% YoY Diluted EPS
$-0.48
▼ 500% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-08-05
Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2020 Earnings Call Transcript
Revenue
$27.38M
▼ 35.9% YoY Diluted EPS
$-0.13
▼ 161.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-05-07
Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2020 Earnings Call Transcript
Revenue
$23.53M
▼ 51.1% YoY Diluted EPS
$-0.20
▼ 183.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-02-05
Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2020 Earnings Call Transcript
Revenue
$29.45M
▼ 15% YoY Diluted EPS
$-0.03
▼ 123.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–37 of 37 webcasts
Key facts
CIK
879407
CUSIP
04280A100
13F (30d)
372 filings
350 filers
Visit website
Investor relations